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Abstract
Background: An unprecedented high proportion of oseltamivir resistant influenza A(H1N1)
viruses emerged in the 2007–08 influenza season. In Norway, two thirds of all tested A(H1N1)
viruses were resistant to the antiviral drug. In order to see if this emergence could be explained by
a drug induced selection pressure, we analysed data on the sales of oseltamivir in Norway for the
years 2002–07.
Methods: We used data from two sources; the Norwegian Drug Wholesales Statistics Database
and the Norwegian Prescription Database (NorPD), for the years 2002–2007. We calculated
courses sold of oseltamivir (Tamiflu®) per 1000 inhabitants per year.
Results: Our data showed that, except for the years 2005 and 2006, sales of oseltamivir were low
in Norway; courses sold per 1000 inhabitants varied between 0.17–1.64. The higher sales in 2005
and 2006 we believe were caused by private stockpiling in fear of a pandemic, and do not represent
actual usage.
Conclusion: A drug induced selection pressure was probably not the cause of the emergence of
oseltamivir resistant influenza A(H1N1) viruses in 2007–08 in Norway.
Background
The 2007–08 influenza season on the Northern Hemi-
sphere was characterized by an unprecedented high pro-
portion of influenza A(H1N1) viruses resistant to the
antiviral drug oseltamivir[1]; a neuraminidase inhibitor
used as prophylaxis or treatment for influenza. This devel-
opment was first detected in and reported by Norway. By
the end of the 2007–08 influenza season in Norway[2],
two thirds of all A(H1N1) viruses tested were resistant
against oseltamivir, the highest proportion recorded in
any country on the Northern Hemisphere[3].
The oseltamivir resistance was caused by a known muta-
tion causing a histidine to tyrosine substitution at the
position 275 in the viral N1 neuraminidase gene. This
substitution is associated with a high-level resistance to
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oseltamivir[4]. The mutation had previously been found
in less than 1% of influenza A viruses tested[5] and had
been associated with low viral fitness and reduced ability
to transmit[6].
Cross-resistance towards another neuraminidase inhibi-
tor zanamivir has previously been shown, but not with
this particular mutation. In accordance with this, the
A(H1N1) viruses detected during the 2007–08 season
remained susceptible to zanamivir.
Many countries, including Norway, have stockpiled osel-
tamivir as a part of the pandemic preparedness, according
to WHO recommendations[7]. In Norway, oseltamivir
has been available as a prescription-only drug since June
2002[8], and is licensed for persons older than one year.
One course equals a five-day treatment with 75 mg × 2
daily. The price of one course is approximately 24 € or 34
USD (January 2009). In order to see if the emergence of
the high proportion of oseltamivir resistant influenza
viruses in Norway in 2007 was caused by a drug induced
selection pressure, we analysed data on the sales of osel-
tamivir in Norway for the years 2002–07.
Methods
We used two different sources of information on sale fig-
ures of oseltamivir (Tamiflu®).
Firstly, we extracted data from the Norwegian Drug
Wholesales Statistics Database. This database is adminis-
tered by the Norwegian Institute of Public Health and
contains complete data on all medicines sold from the
wholesalers to Norwegian pharmacies, hospitals and
nursing homes. Information of sales is available as pack-
ages sold and as number of defined daily doses http://
www.whocc.no/atcddd/. We used population data from
Statistics Norway http://www.ssb.no to calculate courses
sold per 1000 inhabitants. We also extracted data about
sold courses of zanamivir (Relenza®) from this database.
Secondly, we used data from the Norwegian Prescription
Database (NorPD). This database was established in 2004
and is administered by the Norwegian Institute of Public
Health. All Norwegian pharmacies report all prescriptions
filled by outpatients. Thus, these numbers represent a sub-
set of the data in the Wholesales Statistics. The prescrip-
tions can be traced to individuals using a unique personal
identification number. However, a small minority of pre-
scriptions lacks this number. In this study we included all
prescriptions, with or without an id number, with the
assumption that it is unlikely that a person would obtain
oseltamivir several times during one year.
Results
We found that oseltamivir sales in Norway in the years
2004–7 varied between 0.17 – 1.64 courses per 1000
inhabitants per year, except for the years 2005 and 2006
(table 1).
In the same period, zanamivir was sold in very low num-
bers according to the Wholesales Statistics: 2004: 54
courses, 2005: 51 courses, 2006: no courses sold, 2007: 7
courses.
Data from the Wholesales Statistics showed that the high
sales in 2005 and 2006 mainly were due to high sales in
February and October 2005, and in August 2006 (figure
1).
Discussion
Our results show that oseltamivir sales in Norway were
low prior to the 2007 emergence and widespread circula-
tion of oseltamivir resistant influenza A(H1N1) viruses.
Thus, the emergence of oseltamivir resistance does not
seem to be caused by a drug induced selection pressure in
Norway. Furthermore, the persistence of resistance
throughout the season indicates that the resistant viruses
sustained their fitness independently from a selection
pressure by oseltamivir.
Table 1: Courses sold of oseltamivir in Norway 2004–2007, data from the Norwegian Drug Wholesales Statistics Database and the 
NorPD
Wholesale Statistics NorPD
Year Number of courses sold Courses sold pr. 1000 inhabitants Number of courses sold Courses sold pr. 1000 inhabitants
2002* 864 0.19 Data not available Data not available
2003 7465 1.64 Data not available Data not available
2004 766 0.17 764 0.17
2005 65258 14.17 23328 5.06
2006 33006 7.11 4839 1.04
2007 4561 0.97 3478 0.74
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We have no method for measuring the actual usage of
oseltamivir, but we believe that the higher sales and pre-
scription figures in 2005 and 2006 can be explained by
the public's stockpiling in fear of a pandemic, and does
not represent actual usage in this period. This is supported
by the lack of relationship between increased influenza
activity[9] and the highest peaks of sales of oseltamivir in
2005 and 2006. In 2005 there was an increased media
attention on pandemic flu, and private stockpiling of osel-
tamivir was causing empty pharmacies in the beginning of
the year. In the US, increased media attention on the pan-
demic flu also caused private stockpiling of the drug out-
side the influenza-season[10]. In November 2005 the
Norwegian authorities issued an official advice against
private stockpiling of oseltamivir[11].
The difference in numbers from the Wholesales Statistics
and NorPD in 2005–06 might be explained by deviation
from normal dispensing rules by many pharmacies,
because of the mass of total demand in this period. The
consequence was that the complete sales of oseltamivir
were registered in the Wholesales Statistics and not in the
NorPD.
Privately imported drugs following Internet purchases are
not included in our figures, but we believe this represent
a very small amount. Similarly, there may have been
some, but probably not widespread, usage of privately
stockpiled drug during subsequent influenza seasons,
with or without medical consultation.
Conclusion
Our assumption is that use of oseltamivir in Norway was
low prior to the emergence of oseltamivir resistant influ-
enza viruses, as shown by the low sales figures except for
2005 and 2006 when private stockpiling most likely
caused the higher sales. The emergence and widespread
circulation of the oseltamivir resistant influenza A(H1N1)
virus in the 2007–08 season was probably not caused by
a drug induced selection pressure in Norway.
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